THT Conference 2025 - Findings show catheter ablation of the right greater splanchnic nerve (GSN) in patients with heart failure with preserved ejection fraction (HFpEF) reduced estimated stressed blood volume in patients whether the ablation caused clinical benefits or not. This outcome indicates a confirmation of technical success that correlates with prior single-arm study findings.

Dr Marat Fudim (Duke University, Durham, US) joins us to discuss findings supporting REBALANCE-HF (NCT04592445), a randomized, open-label trial investigating the safety and effectiveness of GSN ablation using the Axon System (Axon Therapies, Inc.) in patients with HFpEF. The secondary analysis further investigated the reduction of stressed blood volume calculated with invasively-obtained hemodynamics through rest and exercise. The secondary analysis enrolled a sub-population from REBALANCE-HF who were from centres who accurately recorded cardiac output with rest and exercise.

Interview Questions:
1. What is the reasoning behind the trial?
2. What is the current research landscape for GSN ablation in HF patients?
3. What was the patient population, and what were the key findings?
4. What are your take-home messages?
5. What further research is needed?

Recorded remotely from Durham, US, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.